<p>(<b>A</b>) Cells were incubated for 16 h with the indicated concentrations of etoposide and tested for apoptosis by measuring Parp-1 cleavage by western blot. (<b>B</b>) Apoptosis was confirmed by counting the number of cells with a fragmented nucleus visualized by DAPI staining. (<b>C</b>) Analysis of Parp-1 cleavage in DU-145 cells treated for 16 h with the indicated concentration of cisplatin. (<b>D</b>) Cell proliferation of DU-145 cells treated with or without 5 μM cisplatin measured by (<sup>3</sup>H]-thymidine incorporation. All results represent three independent experiments, including a minimum of two independent DU-145 clones. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.</p
<p>(A,B) Cells were transfected with TASK-1 siRNA or non-silencing siRNA (control siRNA). 48 hours a...
<p>Cells of A549 clones were treated with 2.5 µg/ml dox and harvested at the indicated time points. ...
<p>* Apoptosis was measured through western blot for cleaved caspase 3 and cleaved PARP. (A&D) In ER...
<p>(A) TUNEL assay to evaluate apoptosis (green) in NRK-52E cells exposed to cisplatin or control. N...
<p><b>A)</b> HCT116 clones were either untreated (NT) or treated with 15 µM cisplatin. At the 24 hr ...
<p>Cell apoptosis was diminished in TAp73α-overexpressed cells (SKOV3 C8 and OVCA433 C1) in response...
<p>(A) A549 cells were treated with 100 nM of dasatinib, 1000 nM of AZD0530, or erlotinib with or wi...
<p><b>A</b>) Five diploid clones isolated from Nutlin treated D3 cells (D3 Diploid) and D8 cells (D8...
<p><b>A</b> and <b>B</b>, MTS experiments showed that 18β-GA inhibited cell proliferation of A549 an...
<p>KTC-1 cells were left untreated as controls (<b>A</b>), or treated with 20 MBq/ml <sup>131</sup>I...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
<p>(A) DLD-1 cells were treated with erlotinib (2 μM) and PP242 (1 μM), alone or in combination, for...
<p>(A) Mitochondrial membrane potentials of KYSE140 and EC0156 cells were determined using Mito Trac...
<p>(<b>A</b>) Percentage of dead DU 145 cells (annexin V<sup>+</sup>/PI<sup>-</sup> and annexin V<su...
<p>Parent and resistant cell lines were treated with cisplatin for 72 h. Apoptotic cells, as measure...
<p>(A,B) Cells were transfected with TASK-1 siRNA or non-silencing siRNA (control siRNA). 48 hours a...
<p>Cells of A549 clones were treated with 2.5 µg/ml dox and harvested at the indicated time points. ...
<p>* Apoptosis was measured through western blot for cleaved caspase 3 and cleaved PARP. (A&D) In ER...
<p>(A) TUNEL assay to evaluate apoptosis (green) in NRK-52E cells exposed to cisplatin or control. N...
<p><b>A)</b> HCT116 clones were either untreated (NT) or treated with 15 µM cisplatin. At the 24 hr ...
<p>Cell apoptosis was diminished in TAp73α-overexpressed cells (SKOV3 C8 and OVCA433 C1) in response...
<p>(A) A549 cells were treated with 100 nM of dasatinib, 1000 nM of AZD0530, or erlotinib with or wi...
<p><b>A</b>) Five diploid clones isolated from Nutlin treated D3 cells (D3 Diploid) and D8 cells (D8...
<p><b>A</b> and <b>B</b>, MTS experiments showed that 18β-GA inhibited cell proliferation of A549 an...
<p>KTC-1 cells were left untreated as controls (<b>A</b>), or treated with 20 MBq/ml <sup>131</sup>I...
<p>A549Pt and A549cisR cells were treated for 48 hours with 5 μM and 5 μM or 25 μM cisplatin (cisPt)...
<p>(A) DLD-1 cells were treated with erlotinib (2 μM) and PP242 (1 μM), alone or in combination, for...
<p>(A) Mitochondrial membrane potentials of KYSE140 and EC0156 cells were determined using Mito Trac...
<p>(<b>A</b>) Percentage of dead DU 145 cells (annexin V<sup>+</sup>/PI<sup>-</sup> and annexin V<su...
<p>Parent and resistant cell lines were treated with cisplatin for 72 h. Apoptotic cells, as measure...
<p>(A,B) Cells were transfected with TASK-1 siRNA or non-silencing siRNA (control siRNA). 48 hours a...
<p>Cells of A549 clones were treated with 2.5 µg/ml dox and harvested at the indicated time points. ...
<p>* Apoptosis was measured through western blot for cleaved caspase 3 and cleaved PARP. (A&D) In ER...